C4X DISCOVERY HOLDINGS ORD 1P overview

This announcement contains inside information Strategic Divestment of C4XD's Orexin-1 Receptor Antagonist Programme to Indivior for £15.95 Million Sale encompasses all rights and enables immediate revenue recognition Non-dilutive proceeds to accelerate progress of immuno-inflammatory portfolio MANCHESTER, UK / ACCESSWIRE / August 1, 2023 / C4X Discovery Holdings plc (AIM:C4XD), a pioneering Drug Discovery company, today announces the execution of an asset purchase agreement for Indivior PLC...

EQS-News: C4X Discovery Holdings PLC C4X Discovery signs potential $402mln deal 28.11.2022 / 15:30 CET/CEST The issuer is solely responsible for the content of this announcement. Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 [email protected] News Source: News Direct 28.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services...

C4XD signs exclusive global licence worth up to $402 million 1 with AstraZeneca for the development and commercialisation of NRF2 Activator programme C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company MANCHESTER, ENGLAND / ACCESSWIRE / November 28,...

€3 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme MANCHESTER, UK / ACCESSWIRE / July 6, 2022 / C4X Discovery Holdings plc (AIM:C4XD), a pioneering Drug Discovery company, today announces that it has received a milestone payment of €3 million from Sanofi under the IL-17A Inhibitor programme license agreement entered into in April 2021. Under the terms of the deal, C4XD is entitled to up to a total of €414 million in upfront, pre-clinical,...

C4X Discovery Holdings plc Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme €7 million upfront payment in addition to potential pre-clinical milestones of €11 million, clinical and commercial milestones plus royalties Second major licensing deal with a global pharmaceutical company in commercially attractive markets 12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces...

C4X Discovery Holdings plc Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme €7 million upfront payment in addition to potential pre-clinical milestones of €11 million, clinical and commercial milestones plus royalties Second major licensing deal with a global pharmaceutical company in commercially attractive markets 12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces...

C4X Discovery Holdings plc (“C4XD”, “C4X Discovery” or the “Company”) C4X Discovery and PhoreMost collaboration to accelerate Parkinson’s Disease drug discovery pipeline 25 June 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today entered into a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. The collaboration, focused initially in Parkinson’s Disease, will combine...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......